by In2Pharma | Apr 15, 2021 | News
Belgium The question was raised by some of the members whether it is needed to decommission commercial packages during (re)-labelling to medical samples, Medical Need Program (MNP) products and Investigational Medicinal Products (IMP). After verification in the...
by In2Pharma | May 9, 2019 | News
Belgium On February 8, 2019, the Belgian Official Gazette published a Royal Decree amending both the Royal Decree of 14 December 2006 on medicinal products for human and veterinary use and the Royal Decree of 21 January 2009 concerning instructions for pharmacists....
by In2Pharma | Mar 15, 2019 | News
The Netherlands Since February, all prescription medicines have a unique code and sealed packaging. The purpose of these safety features is to detect counterfeit medicines in the regular distribution channel. Any problem with the code or the seal can be reported...
by In2Pharma | Feb 12, 2019 | News
Belgium In light of the Falsified Medicines Directive, that came into effect on 9th February 2019, FAMHP has issued practical guidelines for the handling of complications during the initial phase of the new verification system. FAMHP and BeMVO have worked out an...
by In2Pharma | Oct 26, 2018 | News
The Netherlands The Falsified Medicines Directive (FMD) (Directive 2011/62/EU) are measures to prevent falsified medicinal products for human use from entering the legal distribution chain. This includes that all outer packaging of prescription-only medicinal products...
